| 廖学斌,黄梦君,贺长林.肝动脉灌注化疗及栓塞术中运用伊立替康与表阿霉素治疗不可切除肝癌的疗效分析[J].安徽医药,2016,20(5):972-975. |
| 肝动脉灌注化疗及栓塞术中运用伊立替康与表阿霉素治疗不可切除肝癌的疗效分析 |
| Comparison of curative effects of irinotecan and pharmorubicin for TACE in patients with unresectable hepatocellular carcinoma |
| 投稿时间：2016-01-28 |
| DOI： |
| 中文关键词: 肝肿瘤 表柔比星 化学疗法,肿瘤,局部灌注 化学栓塞,治疗性 治疗结果 伊立替康 |
| 英文关键词: Liver Neoplasms Epirubicin Chemotherapy,Cancer,Regional Perfusion Chemoembolization,Therapeutic Treatment Outcome rinoteca |
| 基金项目: |
|
| 摘要点击次数: 3495 |
| 全文下载次数: 103 |
| 中文摘要: |
| 目的 比较肝动脉灌注化疗及栓塞术(TACE)中运用伊立替康与表阿霉素治疗不可切除肝癌的疗效。方法 选取行TACE治疗的不可切除肝癌患者100例,根据化疗方案不同分为伊立替康组(n=35)与表阿霉素组(n=65)。比较近期治疗效果、无进展生存期与总生存期、TACE后不良反应。结果 两组患者近期疗效及TACE后不良反应比较差异无统计学意义(P>0.05)。伊立替康组中位无进展生存期为11.2个月,长于表阿霉素组(9.3个月),但差异无统计学意义(P>0.05)；伊立替康组BCLC分级B亚组无进展生存期长于表阿霉素组(P<0.05)。伊立替康组患者1、2年生存率分别为85.7%、45.7%,均高于表阿霉素组(66.2%,21.5%)。伊立替康组及BCLC分级B亚组患者总生存期均长于表阿霉素组(P<0.05)。结论 与表阿霉素传统化疗方案相比,TACE中运用伊立替康可延长不可切除肝癌患者的总生存期,且不良反应无差异。 |
| 英文摘要: |
| Objective To compare the curative effects of irinotecan and pharmorubicin for TACE in patients with unresectable hepatocellular carcinoma.Methods 100 patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization from April 2008 to December 2014 in People’s Hospital of Dujiangyan were assigned into irinotecan group (n=35) and pharmorubicin group (n=65).Recent therapeutic effect,progression free survival and overall survival,adverse reaction after TACE of patients in two groups were compared.Results There was no statistically significant difference in recent therapeutic effect and adverse reaction after TACE between two groups (P>0.05).The median progression free survival of irinotecan group was 11.2 months,longer than that in pharmorubicin group (9.3 months),but the difference was not statistically significant (P>0.05).The median progression free survival of BCLC hierarchical Bsubgroup in irinotecan group was longer than that in pharmorubicin group (P<0.05).The 1-year and 2-year survival rates were 85.7%,45.7%,higher than those in pharmorubicin group (66.2%,21.5%).The overall survival of irinotecan group and BCLC hierarchical Bsubgroup in irinotecan group were longer than those in pharmorubicin group (P<0.05).Conclusions Compared with the traditional chemotherapy of epirubicin,irinotecan in TACE can prolong the overall survival of patients with unresectable hepatocellular carcinoma and there is no difference in adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
